CRIS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Curis Inc (CRIS) is not a strong buy for a beginner investor with a long-term focus at this time. Despite some positive developments in R&D and improved cash runway, the stock's technical indicators are bearish, financial performance is weak, and there are no strong trading signals or significant positive catalysts to justify immediate investment.
The technical indicators for CRIS are bearish. The MACD is negatively expanding, RSI indicates an oversold condition at 9.015, and moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with S2 at 0.513.
R&D expenses decreased, and the company has a cash runway into the second half of
Advancements in the TakeAim Lymphoma study with preliminary data expected at the 2026 ASH Annual Meeting are promising.
Revenue dropped significantly by -65.98% YoY in Q4 2025, and EPS fell by -198.40% YoY. The MACD and RSI indicate a bearish trend, and the stock price has experienced a sharp decline of -17.15% in regular market trading. There is no recent congress trading data or significant insider/hedge fund activity.
In Q4 2025, Curis's revenue dropped to $1.14 million (-65.98% YoY), net income dropped to $19.36 million (-301.25% YoY), and EPS dropped to 1.23 (-198.40% YoY). However, gross margin increased to 100%, up 35.04% YoY.
No specific analyst ratings or price targets for CRIS were provided. The general sentiment from analysts on the MedTech sector suggests cautious optimism for 2026, but sector rotation and regulatory changes pose risks.
